+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "P Selectin"

P Selectin Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

P Selectin Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Sickle Cell Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Sickle Cell Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
From
Vaso-Occlusive Crisis - Pipeline Insight, 2025 - Product Thumbnail Image

Vaso-Occlusive Crisis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Thrombotic Thrombocytopenic Purpura - Pipeline Insight, 2025 - Product Thumbnail Image

Thrombotic Thrombocytopenic Purpura - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Sickle Cell Disease - Competitive landscape, 2023 - Product Thumbnail Image

Sickle Cell Disease - Competitive landscape, 2023

  • Report
  • May 2023
  • 196 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

P-Selectin is a type of hematological drug used to treat a variety of conditions related to the blood, such as thrombosis, inflammation, and cancer. It is a type of cell adhesion molecule that binds to other cells, allowing them to stick together and form clots. P-Selectin is also involved in the process of leukocyte rolling, which is important for the immune system to respond to infection. P-Selectin is used in a variety of treatments, including anticoagulants, anti-inflammatory drugs, and cancer therapies. It is also used in research to study the role of cell adhesion molecules in the development of diseases. The P-Selectin market is highly competitive, with many companies offering products for different applications. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bristol-Myers Squibb. Other companies include AstraZeneca, GlaxoSmithKline, and Roche. Show Less Read more